, including antioxidant and α-glucosidase inhibitory activity, was assayed in vitro. Extracts of ethyl acetate (EtOAC) (TASEA) and n-butanol (n-BuOH) (TASBU) were studied on protective effects of alloxan-induced diabetic rats in vivo. The antioxidant activity was determined by the method of 1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonicacid) (ABTS) and ferric reducing antioxidant power (FRAP) assay. α-Glucosidase inhibitory activity was screened by 96-microplate-based method. The results showed that TASEA had the highest antioxidant activity (DPPH: IC 50 =1.88±0.04 µg/ml, ABTS: IC 50 =1.02±0.04 µg/ml and FRAP=8578.25±59.15 µmol TE/g). TASEA had the highest α-glucosidase inhibitory activity (IC 50 =0.42±0.02 µg/ml). Compared with diabetic control mice, administration of TASEA (1200 and 400 mg/kg) and TASBU (1000 and 300 mg/kg) significantly decreased the level of fasting blood glucose (FSG), postprandial blood glucose (PBG) and malondialdehyde (MDA). Oral administration of TASEA and TASBU could decrease the level of triglyceride (TG) without statistical significance. TASEA (1200 mg/kg) could significantly increase liver glycogen content and decreased the level of total cholesterol (TC) and TASBU (1000 mg/kg) could significantly increase the level of superoxide dismutase (SOD) in serum. The results indicate that TASEA and TASBU had significant antihyperglycemic effects in alloxan-induced diabetic rats.
INTRODUCTION
Diabetes mellitus (DM) is a common metabolic disease characterized by elevated blood glucose levels, resulting from absent or inadequate pancreatic insulin secretion, with or without concurrent impairment of insulin action (Ortiz et al., 2007) . In 2000, the World Health Organization indicated that there were 170 million people with diabetes, and estimated that the number of cases of the disease worldwide will have more than doubled to 366 million by the end of 2030 (Edson et al., 2010 ). Recent researches demonstrate that active free radicals *Corresponding author. E-mail: kangweny@hotmail.com. Tel: (+86)-378-3880680, Fax: (+86)- 378-3880680. can cause many kinds of illness occurrences,such as cancer, diabetes, neurodegenerative and cardiovascular disease (Gao et al., 2011; Valko et al., 2007) . Oxidative stress is characterized by overt generation of free radicals and increased susceptibility of the organism towards oxidative damage. Postprandial hyperglycemic is an important factor for DM. The cardiovascular toxicity of postprandial hyperglycemic is mediated by oxidant stress, which is directly proportional to the increase in glucose after a meal. Oxidative stress may become therapeutics of diabetes and its complications. Therefore, in currently, to investigate the active and safe natural antioxidant activities is a prime focus.
α-Glucosidase inhibitor drugs like acarbose and voglibose have shown promise in reducing postprandial hyperglycemia and sensitivity of postprandial oxidative stress along with reducing the increased risk of cardiovascular diseases (Kawamura et al., 1998) . Plants and microorganisms have been a rich source of α-glucosidase inhibitors and screening of α-glucosidases inhibitors from plants and synthetic sources is very important for diabetes (Li et al., 2004; Shibano et al., 2008) .
Trapa acornis Nakano, belongs to the Trapaceae family, is one of the most popular vegetables and fruits in China as unique taste and medical functions of its pulps. The genus Trapa occurs widely throughout tropical, subtropical and temperate regions of Asia, Africa and central Europe (Institute of Botany, Chinese Academy of Sciences. 2004). In China, the genus Trapa is mainly distributed in the south of Yangtze River and many of its species have been used as traditional medicinal herbs to treat ulcer and cancer. Phytochemical research showed that flavonoids, alkaloids and sterols were main compounds in the shells of Trapa species (Niu et al., 2003; Shang et al., 2007) , and pharmacological investigation showed that extract of shells of Trapa species had anti-cancer activity (Xie, 2011) . However, there was no report concerning antioxidant, α-glucosidase inhibitory activities in vitro and antihyperglycemic of T. acornis shell (TAS) for alloxaninduced diabetic rats in vivo. In this work, antioxidant and α-glucosidase inhibitory activities of TAS extracts were assayed and their antihyperglycemic for alloxan-induced diabetic rats was studied.
MATERIALS AND METHODS

Plant material and fraction preparation
The TAS was collected in September, 2009 in Jiaxing, Hangzhou province, China, and identified by Professor Changqin Li (Institute of Chinese Materia Medica, Henan University). A voucher specimen was deposited in the Institute of Chinese Materia Medica, Henan University (No. 0910103).
The air dried TAS (3.9 kg) was extracted three times with 80% ethanol for 2 d at room temperature. After evaporation of solvent in vacuo, the concentrated extract was suspended in water and extracted successively with petroleum ether, ethyl acetate (EtOAC) extract and n-butanol (n-BuOH), respectively.
The solution was concentrated under reduced pressure to yield petroleum ether extract (TASPE), EtOAC extract (TASEA) and nbutanol (TASBU).
Materials and protocols in vitro
Materials in experiments in vitro
α-Glucosidase (EC 3.2.1.20), 4-nitrophenyl-α-D-glucopyranoside (PNPG, 026K1516) and acarbose (Lot 16869), dimethyl sulfoxide (DMSO), gallic acid propyl (PG), butyl-p-hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) from Sigma Chemical Co.. 1,1-Diphenyl-2-picrylhydrazyl (DPPH) from Tokyo Chemical Industry Co. 2,4,6-Tripyridyl-S-triazine (TPTZ) from Acros organics. 6-Hydroloxy-2,5,7,8-tetramethyl -chroman-2-carboxylic acid (Trolox) from Aldrich. 2,2´-Azino-bis(3-ethylbenzo-thiazoline-6-sulfonicacid) (ABTS) from Fluka.
Antioxidant activity using 1,1-Diphenyl-2-picrylhydrazyl (DPPH) assay DPPH radical scavenging activity was assayed according to the method of Li et al. (2011) . 0.1 ml different extracts of TAS in methanol had been mixed with 3.5 ml DPPH methanol solution (0.06 mmol/L).
The solution was measured at 515 nm after 30 min at room temperature with PG, BHA and BHT as positive control. The antioxidant activity was expressed as an IC50 value, that is, the concentration in µg/ml that inhibits DPPH· absorption by 50%, and was calculated from the concentration-effect linear regression curve. All reactions were carried out with three replications.
Antioxidant
activity using 2,2´-azino-bis(3-ethylbenzothiazoline-6-sulfonicacid) (ABTS) assay Scavenging activity on ABTS radical different extracts of TAS was evaluated in accordance with the literature (Li et al., 2008) . The different extracts of TAS (0.15 ml) were mixed with ABTS radical stock solution (2.85 ml) and incubated at 37°C. The a bsorbance was observed at 734 nm after 10 min with PG, BHA and BHT as positive control.
The percentage inhibition of ABTS + was calculated using the formula: %Inhibition = [(A0-A1)/A0]×100, where A0 was the absorbance of the control and A1 was the absorbance of the sample and the standard compound. All reactions were carried out with three replications.
Ferric reducing antioxidant power (FRAP) reducing activity assay
According to the literature (Thaipong et al., 2006) , the different extracts fractionation of TAS (0.2 ml) and fresh prepared TPTZ stock solution (3.8 ml) were mixed and incubated at 37°C for 30 min. The absorbance was measured at 593 nm. Trolox was used as a reference standard. The standard curve was linear between 25 and 400 µmol/L Trolox. Results were expressed in µmol Trolox equivalents (TEAC) (TE)/g sample. In this study, RACT50 was used to express Trolox equivalent (RACT50 = the concentration of Trolox cleared 50% free radical/the concentration of compound or condensate cleared 50% free radical). All reactions were carried out with three replications.
α-Glucosidase inhibition assay
The α-glucosidase-inhibitory activity was screened by the method of the microplate-based method based on PNPG as substrate according to the literature (Kang et al., 2009) . The samples were dissolved in DMSO and diluted with 112 µl phosphate buffer (pH 6.8) and α-glucosidase (20 µl, 0.2 U/L) were mixed and incubated at 37°C for 15 min. Then, substrate solution (20 µl, 2.5 mM PNPG prepared in the same buffer) was added. The reaction was terminated by adding 80 µl of 0.2 M Na2CO3 solution after incubated at 37°C for 15 min.
Enzymatic activity was quantified by measuring the p-nitrophenol released from PNP-glycoside at 405 nm wavelength in a 96 microplate reader. Enzymatic inhibition data were expressed as IC50 values (concentration of inhibitor required for 50% inhibition against α-glucosidase). All reactions were carried out with three replications. Acarbose was used as positive control. 
Experimental design and treatment schedule
Mice diabetic model was established by tail vein injection of alloxan which a freshly prepared solution of alloxan (80 mg/kg body weight) in 0.9% Nacl after overnight fasting for 12 h. Fasting for 12 h after injection of alloxan, fasting blood glucose (FSG) was determined in the 3rd day of the study. Mice with the blood glucose level more than 11.0 mmol/L were taken as which were successful induction of diabetes for experiments. Experimental mice were divided into six groups of ten mice each. Group I (normal control with distilled water), Group II (diabetic control with distilled water), Group III (diabetic mice treated with 1200 mg/kg b.w. TASEA), Group IV (diabetic mice treated with 400 mg/kg b.w. TASEA), Group V (diabetic mice treated with 1000 mg/kg b.w. TASBU), Group VI (diabetic mice treated with 300 mg/kg b.w. TASBU) and Group VII (diabetic mice treated with 75 mg/kg b.w. acarbose). The duration of treatment was 10 d by intragastric administration. Blood was collected from the eyes after 2 h by intragastric administration in the 10 d. Blood was collected from the eyes after fasting for 12 h, then the animals were sacrificed by cervical dislocation, the liver, kidney and spleen were removed promptly, and weighed. Blood samples were centrifuged (3000 rpm for 15 min at 4°C) for sepa rating the serum. After that, the serum was stored at −20°C aft er separation for the following biochemical analysis. The tissues were also stored at−20°C until required.
Biochemical analyses
The level of blood glucose, glycogen content in the liver, TC, TG, SOD and MDA levels in serum were measured following the commercial kit's instructions.
Statistical analysis
All the grouped data were statistically evaluated with SPSS 17.0 software. Hypothesis testing methods included one-way analysis of variance (ANOVA) followed by least significant difference (LSD) test. The results were considered statistically significant if the p values were 0.05 or less. All results are expressed as mean± standard deviation (SD) for ten mice in each group.
RESULTS
α-Glucosidase inhibitory activity
In Table 1 , the α-glucosidase inhibitory activity of TASPE (IC 50 =14.43±0.12 µg/ml), TASEA (IC 50 =0.42±0.02 µg/ml) and TASBU (IC 50 =1.02±0.06 µg/mL) was higher than that of acarbose (IC 50 =1103.01±112.63 µg/ml) as positive control. TASEA had the highest α-glucosidase inhibitory activity. In Figure 1 , the α-glucosidase inhibitory activities of TASPE, TASEA and TASBU exhibited strong activity in dose dependent manner. The result showed that TAS might be a good source of natural α-glucosidase inhibitor use for the therapy of hyperglycemic and its complication.
Antioxidant activity of different extract of Trapa acornis shell (TAS)
The antioxidant activity of TAS and positive control determined by DPPH, ABTS and FRAP assays were showed in Table 2 , Figures 2 and 3 . In DPPH assay (Table 2) , the antioxidant activity of TASPE (IC 50 =13.97±0.06 µg/ml), TASEA (IC 50 =1.88±0.04 µg/ml) and TASBU (IC 50 =3.27±0.03 µg/ml) were higher than that of BHT (IC 50 =18.72±0.50 µg/ml). TASEA (IC 50 = 1.88±0.04 µg/ml) was higher than that of BHA (3.20±0.04 µg/ml).
In Figure 2 , at a dose of 27.78, 6.94 and 6.94 µg/mL, the scavenging abilities of TASPE, TASEA and TASBU on DPPH radicals was 86.93, 92.36 and 91.01%, respectively and improving the concentration, the inhibition rate almost in a straight line. In ABTS assay, the antioxidant activity of TASEA (IC 50 =1.02±0.04 µg/ml) was higher than that of BHT (IC 50 =7.77±0.01 µg/ml) and BHA (1.88±0.01 µg/ml). Figures 2 and 3 showed that the free radical scavenging capacity of extracts of TAS was in relation to concentration and extraction solvent. In FRAP assay, the antioxidant activity of TASEA (RACT50=8578.25±59.15 µmol/g) was higher than that of BHT (1581.68±97.41 µmol/g) and lower than that of BHA and PG. Three extracts of antioxidant activities according to the following as TASEA > TASBU >TASPE.
Effect of Trapa acornis shell EtOAC (TASEA) and Trapa acornis shell n-BuOH (TASBU) treatment on fasting blood glucose (FSG)
In Table 3 , compared with normal control group, the level of FSG in serum of diabetic control group showed a significant increase (P<0.01) and it indicated that the model of alloxan-induced diabetic mice was established. FSG levels of diabetic control are higher than that of normal control group throughout the experimental period. 
Concentration (µg/ml)
Concentration (µg/ml) acarbose to diabetic mice for 10 d, the level of FSG was decreased significantly (P < 0.01). Daily treatment with TASEA (1200 and 400 mg/kg), TASBU (1000 and 300 mg/kg) and acarbose (75 mg/kg) for 10 d to fall in FSG levels by 13.13, 9.53, 13.81 and 10.16 mmol/L, respectively. Intragastric administration of TASEA (1200 and 400 mg/kg), TASBU (1000 and 300 mg/kg) was not significant (P > 0.05) compared with acarbose (positive control) group. In Table 4 , compared with normal control, diabetic control group has a significant increase in postprandial blood glucose (PBG) (P < 0.05) throughout the experimental period. Intragastric administration of TASEA (1200 and 400 mg/kg) and TASBU (1000 and 300 mg/kg), a significant reduction (P < 0.05) in PBG was observed after 2 h compared with diabetic control. The effect of TASEA (1200 mg/kg) and TASBU (1000 mg/kg) was similar to that of acarbose (P > 0.05). It showed that TASEA and TASBU dose groups had antihyperglycemic activities. In Table 5 , the level of hepatic glycogen was significantly decreased in diabetic control compare with normal group. After 10 d, the level of hepatic glycogen was significantly increased in TASEA (1200 mg/kg) group (P < 0.05) compared with diabetic control group, but other treatment group without statistical significance (p > 0.05). In Table 6 , there was significant increase in the level of TC and TG in diabetic control group compared with normal control group. When diabetic mice were treated by administration of TASEA (1200 mg/kg) for 10 d, the level of TC was significantly decreased (P < 0.05), but not significantly reduced (P > 0.05) in TASEA (400 mg/kg) group and TASBU (1000 and 300 mg/kg) compared with diabetic control group. There were not any significant differences in TG levels in any treated groups compared with diabetic control group (P > 0.05). In Table 7 , the level of SOD was significantly reduced and the content of MDA was significantly increased in serum of diabetic control group compared with normal control group. The level of SOD in TASBU (1000 mg/kg) and acarbose (75 mg/kg) significantly increased (P < 0.05) compared with alloxan-induced diabetic group treatment. The TASEA (400 and 1200 mg/kg), TASBU (300 and 1000 mg/kg) treatment group significantly decreased (P < 0.05) in MDA compared with diabetic control group.
DISCUSSION
Normally, body organisms are able to control and counter the free radical mediated oxidative damage. However, in DM, oxidative stress could play an important role in the onset and progression of the disease (Sun et al., 2007; Ani and Naidu, 2008) . Studies have shown that there was exists phenomenon that MDA was significantly increased and SOD was significantly decreased in animal models of DM. Endogenous antioxidant enzymes SOD are responsible for the detoxification of deleterious oxygen radicals (Ramesh and Pugalendi, 2006; Sandesh et al., 2010) . In this experiment, the antioxidant activity of TAS was analyzed by three methods in vitro. The results of three methods were summarized that the TASPE, TASEA and TASBU had strong antioxidant activity, and TASEA had the highest antioxidant activity in vitro. Administration of TASEA (1200 and 400 mg/kg) and TASBU (1000 and 300 mg/kg) significantly decreased MDA and treatment with TASBU (1000 mg/kg) significantly increased (P<0.05) the level of SOD compared with alloxan-induced diabetic group which could be due to decreased lipid peroxidation and/or decreased utilization. By reducing the level of MDA and increasing SOD to enhance antioxidant capability and protect the body to further oxidative damage from free radicals in diabetic mice, which play the role of hypoglycemic effect.
Alloxan causes a massive reduction in insulin release by the destruction of the β-cells of the islets of langerhans, inducing hyperglycaemia (Fisher, 1985) . Glycogen is the primary intracellular storable form of glucose and its level in liver directly indicates reflection of insulin activity because it regulates glycogen deposition by stimulating glycogen synthase and inhibiting glycogen phosphorylase (Camilia et al., 2011) . The present study reports that, a significant reduction of PBG levels in diabetic rats was observed in long-term treatment with plant extract and it was compared with that of Metformin which is considered as an insulin sensitizer (Hundal and Inzucchi, 2003) . These effects might have been due to interference on absorption of dietary carbohydrates as well as disaccharides in small intestine or facilitate utilization of glucose by peripheral tissues (Aboozar et al., 2011) . α-Glucosidase inhibitors could competitively inhibit α -glycosidase activity and delay or inhibit the absorption of glucose (Seifath et al., 1998) . To understand the mechanisms by which TAS extract decrease PBG, α-glucosidase inhibitory activity of the crude extract in vitro were investigated. The results indicate that TASPE, TASEA and TASBU had strong α-glucosidase inhibitory activity in vitro; TASEA had the strongest α-glucosidase inhibition. TASEA (1200 and 400 mg/kg) and TASBU (1000 and 300 mg/kg) significantly decreased the level of FSG, PBG. TASEA (1200 mg/kg) could significantly increase liver glycogen content and decreased the level of TC, oral administration of TASEA and TASBU could decrease the level of TG without statistical significance.
Conclusion
Antioxidant activities, and α-glucosidase inhibitory effect assay, TASEA and TASBU showed potent antioxidant activity and α-glucosidase inhibitory effect in vitro, The result showed that, TASPE, TASEA and TASBU had the higher antioxidant activity and α-glucosidase inhibitory effect. TASEA had the highest antioxidant activity and α-glucosidase inhibitory effect in vitro. TASEA and TASBU had significant antihyperglycemic effects in alloxaninduced diabetic rats. Hence, it is may be used in treating diabetes. ABBREVIATIONS: TASEA, Trapa acornis shell EtOAC; TASBU, Trapa acornis shell n-BuOH; DPPH, 1,1-Diphenyl-2-picrylhydrazyl; ABTS, 2,2´-Azino-bis(3-ethylbenzo-thiazoline-6-sulfonicacid); FRAP, ferric reducing antioxidant power; FSG, fasting blood glucose; PBG, postprandial blood glucose; MDA, malondialdehyde; TG, triglyceride; TC, total cholesterol; SOD, superoxide dismutase; EtOAC, ethyl acetate; n-BuOH, nbutanol; DM, diabetes mellitus; TAS, Trapa acornis shell; TASPE, petroleum ether extract; DMSO, dimethyl sulfoxide; PG, gallic acid propyl; BHA, butyl-p-hydroxyanisole; BHT, butylated hydroxytoluene; TPTZ, 2,4,6-Tripyridyl-S-triazine; PNPG, 4-nitrophenyl-α-D-glucopyranoside; Trolox, 6-Hydroloxy-2,5,7,8-tetramethyl -chroman-2-carboxylic acid.
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